Adm1n at 11:01, 15 February 2015

2015-02-15T11:01:56Z

Adm1n: Created page with "'''AB-005 or [1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone''' is a designer drug offered by online vendors as a cannabimimetic a..."

2015-02-15T11:01:23Z

Created page with "'''AB-005 or [1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone''' is a designer drug offered by online vendors as a cannabimimetic a..."

New page

'''AB-005 or [1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone''' is a designer drug offered by online vendors as a cannabimimetic agent. The structure and pharmacological activity of AB-005 was published in 2010, prior to its commercial availability in 2012, where it was reported to have high affinity for both CB1 (Ki = 5.5 nM) and CB2 receptors (Ki = 0.48 nM).[1] AB-005 features groups found in other previously reported synthetic cannabinoids: the tetramethylcyclopropane group of [[UR-144]] and [[XLR-11]] as well as the (1-methyl-2-piperidinyl)methyl substituent of [[AM-1248]] and [[AM-1220]]. No information regarding the in vivo activity of AB-005 has been published, and only anecdotal reports are known of its psychoactivity in humans.

== Legal status ==

Psychoactive products in New Zealand containing this drug have been given interim approval under recent psychoactive substances legislation.

==See also==

* [[AB-001]]
* [[AM-1248]]
* [[AM-1220]]
* [[JWH-018]]
* [[UR-144]]
* [[XLR-11 (drug)|XLR-11]]

← Older revision		Revision as of 11:01, 15 February 2015
Line 1:		Line 1:
−	'''AB-005 or [1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone''' is a designer drug offered by online vendors as a cannabimimetic agent. The structure and pharmacological activity of AB-005 was published in 2010, prior to its commercial availability in 2012, where it was reported to have high affinity for both CB1 (Ki = 5.5 nM) and CB2 receptors (Ki = 0.48 nM).[1] AB-005 features groups found in other previously reported synthetic cannabinoids: the tetramethylcyclopropane group of [[UR-144]] and [[XLR-11]] as well as the (1-methyl-2-piperidinyl)methyl substituent of [[AM-1248]] and [[AM-1220]]. No information regarding the in vivo activity of AB-005 has been published, and only anecdotal reports are known of its psychoactivity in humans.	+	'''AB-005 or [1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone''' is a designer drug offered by online vendors as a cannabimimetic agent. The structure and pharmacological activity of AB-005 was published in 2010, prior to its commercial availability in 2012, where it was reported to have high affinity for both CB1 (Ki = 5.5 nM) and CB2 receptors (Ki = 0.48 nM).[1] AB-005 features groups found in other previously reported synthetic cannabinoids: the tetramethylcyclopropane group of [[UR-144]] and [[XLR-11 (drug)\|XLR-11]] as well as the (1-methyl-2-piperidinyl)methyl substituent of [[AM-1248]] and [[AM-1220]]. No information regarding the in vivo activity of AB-005 has been published, and only anecdotal reports are known of its psychoactivity in humans.

AB-005 - Revision history

Adm1n at 11:01, 15 February 2015

Adm1n: Created page with "'''AB-005 or [1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone''' is a designer drug offered by online vendors as a cannabimimetic a..."